AbbVie price target raised to $220 from $214 at BMO Capital

BMO Capital raised the firm’s price target on AbbVie to $220 from $214 and keeps an Outperform rating on the shares as part of a broader research note previewing Q3 results in BioPharma. The company’s Skyrizi and Rinvoq are now well-appreciated on the Street as significant growth levers within AbbVie’s portfolio, though Q3 consensus continued to underestimate the growth seen from scripts in the quarter and over the previous quarters, the analyst tells investors in a research note.